Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291589 | 0.79 | GAA (0.36) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL8588484 | 0.71 | MAOA (0.35) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL186955 | 0.65 | — | — | |
| SCHEMBL30484685 | 0.65 | — | — | |
| SCHEMBL3128 | 0.65 | — | — | |
| SCHEMBL2851479 | 0.65 | — | — | |
| SCHEMBL9050619 | 0.63 | MAOA (0.45) | MAOAMAOBOXTR | |
| SCHEMBL105430 | 0.62 | MAOA (0.39) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL241643 | 0.62 | OXTR (0.42) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL453819 | 0.62 | MAOA (0.39) | GAANPSR1MAOAMAOBOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2060 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | claimed |
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | claimed |
| EP-4294382-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Merck Sharp & Dohme LLC (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230390237-A1 | IMMUNOMODULATING UREA AZALIDES | ZOETIS SERVICES LLC | 2023-12-07 | — | — | US | claimed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230265111-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | claimed |
| WO-2023151662-A1 | ANDROGEN RECEPTOR ACTIVITY REGULATOR AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2023-08-17 | — | — | WO | claimed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | claimed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | claimed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | claimed |
| EP-1428817-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR PRODUCING THESE, AND PEST CONTROL AGENT CONTAINING THESE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2004-06-16 | — | — | EP | claimed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | claimed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | claimed |
| US-5739130-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS, MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-14 | — | — | US | claimed |
| US-5583135-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS OR MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-10 | — | — | US | claimed |
| JP-H08511514-A | — | — | 1996-12-03 | — | — | JP | claimed |
| WO-1994029295-A1 | HETEROCYCLIC DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-22 | — | — | WO | claimed |